DK1819227T3 - Farmaceutisk formulering af decitabin - Google Patents
Farmaceutisk formulering af decitabinInfo
- Publication number
- DK1819227T3 DK1819227T3 DK05853560.0T DK05853560T DK1819227T3 DK 1819227 T3 DK1819227 T3 DK 1819227T3 DK 05853560 T DK05853560 T DK 05853560T DK 1819227 T3 DK1819227 T3 DK 1819227T3
- Authority
- DK
- Denmark
- Prior art keywords
- decitabine
- methods
- pharmaceutical formulation
- pharmaceutical formulations
- formulations
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/009,540 US20060128653A1 (en) | 2004-12-10 | 2004-12-10 | Pharmaceutical formulation of decitabine |
PCT/US2005/044676 WO2006071491A1 (en) | 2004-12-10 | 2005-12-08 | Pharmaceutical formulation of decitabine |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1819227T3 true DK1819227T3 (da) | 2011-05-30 |
Family
ID=36584811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05853560.0T DK1819227T3 (da) | 2004-12-10 | 2005-12-08 | Farmaceutisk formulering af decitabin |
Country Status (15)
Country | Link |
---|---|
US (1) | US20060128653A1 (da) |
EP (1) | EP1819227B1 (da) |
JP (1) | JP5227029B2 (da) |
AT (1) | ATE497770T1 (da) |
AU (1) | AU2005322369B2 (da) |
CA (1) | CA2589052A1 (da) |
CY (1) | CY1111433T1 (da) |
DE (1) | DE602005026313D1 (da) |
DK (1) | DK1819227T3 (da) |
ES (1) | ES2360125T3 (da) |
HK (1) | HK1102991A1 (da) |
PL (1) | PL1819227T3 (da) |
PT (1) | PT1819227E (da) |
SI (1) | SI1819227T1 (da) |
WO (1) | WO2006071491A1 (da) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US20070105792A1 (en) * | 2005-11-04 | 2007-05-10 | Dimartino Jorge F | Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases |
US20090075920A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched decitabine |
US7635773B2 (en) * | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
ES2525257T3 (es) * | 2009-02-25 | 2014-12-19 | Supratek Pharma, Inc. | Composiciones de ciclopolisacárido y de bendamustina |
US8383663B2 (en) * | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
CA2930119C (en) | 2010-10-19 | 2019-10-29 | University Of Miami | Assays, methods and kits for predicting renal disease and personalized treatment strategies |
WO2012106299A1 (en) * | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
ES2547920T3 (es) * | 2011-07-01 | 2015-10-09 | Fondazione Istituto Insubrico Di Ricerca Per La Vita | Un complejo de tomoxiprol amorfo y ciclodextrina con una rápida velocidad de disolución y procedimiento para su preparación |
AU2012302051B2 (en) | 2011-08-30 | 2017-04-27 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
PT2814849T (pt) | 2012-02-15 | 2020-03-04 | Cydex Pharmaceuticals Inc | Processo de fabrico para derivados de ciclodextrina |
JP2015508846A (ja) | 2012-02-28 | 2015-03-23 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 |
US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
JP6491089B2 (ja) | 2012-04-13 | 2019-03-27 | エル アンド エフ リサーチ,リミテッド ライアビリティー カンパニー | シクロデキストリンを使用するための方法 |
US9493500B2 (en) | 2012-07-19 | 2016-11-15 | Richard Daifuku | Fluorinated pyrimidine analogs and methods of use thereof |
WO2014066274A1 (en) | 2012-10-22 | 2014-05-01 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
ES2877103T3 (es) * | 2013-03-15 | 2021-11-16 | Epigenetics Pharma Llc | Análogos de pirimidina fluorados y métodos de uso de los mismos |
JP2016513699A (ja) * | 2013-03-15 | 2016-05-16 | エピザイム,インコーポレイティド | 癌の治療のための注射製剤 |
JP6797692B2 (ja) * | 2014-02-20 | 2020-12-09 | バクサート インコーポレイテッド | 小腸送達のための製剤 |
MY182793A (en) | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
HUE063851T2 (hu) | 2014-08-22 | 2024-02-28 | Cydex Pharmaceuticals Inc | Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására |
US20170290765A1 (en) * | 2014-09-17 | 2017-10-12 | Epizyme, Inc. | Injectable formulations for treating cancer |
CN104887632B (zh) * | 2015-05-25 | 2017-10-24 | 连云港杰瑞药业有限公司 | 一种地西他滨冻干制剂的制备方法及其产品 |
US11433146B2 (en) | 2015-06-12 | 2022-09-06 | Vaxart, Inc. | Formulations for small intestinal delivery of RSV and norovirus antigens |
EP3316685A4 (en) * | 2015-07-02 | 2019-03-13 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized Pharmaceutical Compositions |
WO2017096357A1 (en) | 2015-12-03 | 2017-06-08 | Epidestiny, Inc. | Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof |
WO2019025863A2 (en) | 2017-08-03 | 2019-02-07 | Otsuka Pharmaceutical Co., Ltd. | MEDICAMENT COMPOUND AND METHODS OF PURIFICATION |
WO2023203249A1 (en) * | 2022-04-22 | 2023-10-26 | Universität Heidelberg | Composition comprising cytidine analogs and uses and methods thereof |
WO2024028790A1 (en) * | 2022-08-03 | 2024-02-08 | Beren Therapeutics P.B.C. | Compositions and methods for treating sickle cell disease |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2012888C3 (de) * | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden |
US4684630A (en) * | 1983-08-24 | 1987-08-04 | Repta Arnold J | Method of parenterally delivering drugs and related compositions |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
US5736531A (en) * | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5856090A (en) * | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
US5856094A (en) * | 1995-05-12 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Method of detection of neoplastic cells |
US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
RU98113785A (ru) * | 1995-12-22 | 2000-06-10 | Ист Каролина Юниверсити (US) | Агент и способ лечения заболеваний, связанных с чрезмерной экспрессией цитидиндезаминазы или дезоксицитидинзаминазы |
US6423692B2 (en) * | 1997-04-24 | 2002-07-23 | Dana-Farber Cancer Institute, Inc. | Method of enhancing the effectiveness of DCK phosphorylated molecules |
US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
AU5128999A (en) * | 1998-07-24 | 2000-02-14 | Yeda Research And Development Co. Ltd. | Prevention of metastasis with 5-aza-2'-deoxycytidine |
US20020136709A1 (en) * | 2000-12-12 | 2002-09-26 | Nucleus Remodeling, Inc. | In vitro-derived adult pluripotent stem cells and uses therefor |
US20030165864A1 (en) * | 2001-01-16 | 2003-09-04 | Lasek Amy W. | Genes regulated by DNA methylation in tumor cells |
US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
US20030013099A1 (en) * | 2001-03-19 | 2003-01-16 | Lasek Amy K. W. | Genes regulated by DNA methylation in colon tumors |
EP2283845A1 (en) * | 2001-04-26 | 2011-02-16 | pSivida Inc. | Sustained release drug delivery system containing codrugs |
US20030045497A1 (en) * | 2001-07-27 | 2003-03-06 | Geneinvent Bbl Ab | Methylation resistant vectors |
IN2014DN10834A (da) * | 2001-09-17 | 2015-09-04 | Psivida Inc | |
US20030147813A1 (en) * | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
EP1485082A4 (en) * | 2002-02-19 | 2009-12-30 | Xenoport Inc | PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS |
US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
WO2005014010A1 (en) * | 2003-07-24 | 2005-02-17 | Eli Lilly And Company | Pharmaceutical composition comprising gemcitabine and cyclodextrines |
US20060063735A1 (en) * | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
-
2004
- 2004-12-10 US US11/009,540 patent/US20060128653A1/en not_active Abandoned
-
2005
- 2005-12-08 CA CA002589052A patent/CA2589052A1/en not_active Abandoned
- 2005-12-08 AT AT05853560T patent/ATE497770T1/de active
- 2005-12-08 JP JP2007545673A patent/JP5227029B2/ja active Active
- 2005-12-08 DE DE602005026313T patent/DE602005026313D1/de active Active
- 2005-12-08 EP EP05853560A patent/EP1819227B1/en active Active
- 2005-12-08 ES ES05853560T patent/ES2360125T3/es active Active
- 2005-12-08 SI SI200531272T patent/SI1819227T1/sl unknown
- 2005-12-08 WO PCT/US2005/044676 patent/WO2006071491A1/en active Application Filing
- 2005-12-08 PT PT05853560T patent/PT1819227E/pt unknown
- 2005-12-08 PL PL05853560T patent/PL1819227T3/pl unknown
- 2005-12-08 DK DK05853560.0T patent/DK1819227T3/da active
- 2005-12-08 AU AU2005322369A patent/AU2005322369B2/en active Active
-
2007
- 2007-10-24 HK HK07111443.3A patent/HK1102991A1/xx unknown
-
2011
- 2011-04-28 CY CY20111100417T patent/CY1111433T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005322369A1 (en) | 2006-07-06 |
EP1819227A1 (en) | 2007-08-22 |
JP2008523096A (ja) | 2008-07-03 |
JP5227029B2 (ja) | 2013-07-03 |
EP1819227A4 (en) | 2008-07-23 |
CY1111433T1 (el) | 2015-08-05 |
AU2005322369B2 (en) | 2010-10-28 |
CA2589052A1 (en) | 2006-07-06 |
PL1819227T3 (pl) | 2011-07-29 |
ES2360125T3 (es) | 2011-06-01 |
US20060128653A1 (en) | 2006-06-15 |
HK1102991A1 (en) | 2007-12-14 |
EP1819227B1 (en) | 2011-02-09 |
PT1819227E (pt) | 2011-04-29 |
SI1819227T1 (sl) | 2011-06-30 |
WO2006071491A1 (en) | 2006-07-06 |
ATE497770T1 (de) | 2011-02-15 |
DE602005026313D1 (de) | 2011-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1819227T3 (da) | Farmaceutisk formulering af decitabin | |
WO2006063111A3 (en) | Pharmaceutical formulations cytidine analogs and derivatives | |
LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
CY1119865T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον | |
WO2006029081A3 (en) | Nucleoside-lipid conjugates, their method of preparation and uses thereof | |
LTC1620113I2 (lt) | Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui | |
ATE407928T1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
HK1116073A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
EA200802213A1 (ru) | Способы лечения заболеваний крови | |
BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
MX2007010996A (es) | Nuevas composiciones de liposomas. | |
CY1113323T1 (el) | Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου | |
GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
SE0300010D0 (sv) | Novel Compounds | |
BRPI0513184A (pt) | derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
SE0401342D0 (sv) | Therapeutic compounds | |
PL1809288T3 (pl) | Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych | |
BRPI0513287A (pt) | derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica | |
WO2006108679A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer |